Top Pharma Stocks Compared: Sun Pharma vs Cipla vs Mankind Pharma vs Torrent Pharma vs Laurus Labs on Price, Valuation, Q2 FY27 Results and Risks

Pharma stocks compared puts Sun Pharma, Cipla, Mankind Pharma, Torrent Pharma and Laurus Labs side by side on previous close, market capitalisation, valuation and Q2 FY27 numbers. The group spans global generics, domestic branded medicines and ingredient makers, so the valuation range is wider than in most sectors.

All five companies have filed their September 2026 quarter, so every result below is Q2 FY27 and is shown in rupee crore. Pharma shares often behave differently from the broader market, so the Nifty Pharma page and the Sensex page give a useful reference point before you read the tables.

Click Here – Get Free Investment Predictions

Pharma Stocks Compared: Five Different Business Models

The pharma stocks compared here are Sun Pharma, Cipla, Mankind Pharma, Torrent Pharma and Laurus Labs. Sun Pharma is the largest by market capitalisation at Rs 4,24,202 crore. Previous closes run from Rs 1,387.00 for Cipla to Rs 4,595.00 for Torrent Pharma, which is why a side-by-side look at value rather than price is more useful. This pharma stocks compared list is the base for every table that follows.

Stock	Previous close (Rs)	Market cap (Rs crore)
Sun Pharma	1,770.00	4,24,202
Cipla	1,387.00	1,11,648
Mankind Pharma	2,481.20	1,02,196
Torrent Pharma	4,595.00	1,74,402
Laurus Labs	2,348.00	1,26,811

A quick look at the business behind each ticker puts the numbers in context. Sun Pharma is India's largest pharmaceutical company with a growing specialty medicines portfolio, while Cipla is a pharma major with strength in respiratory medicines and generics across India and export markets. Mankind Pharma is a leading domestic formulations company with a wide field force and strong brands, and Torrent Pharma is a branded formulations company with chronic therapy strength in India and international markets. To compare pharma stocks properly, line up price to earnings, operating margin and revenue growth before forming a view.

Rounding out the group, Laurus Labs is a pharma maker focused on active ingredients, formulations and contract development work. A fair pharma stock comparison looks at what each company actually earns from, not only at the share price. Whenever you compare pharma stocks, do not expect a low multiple to be the main attraction.

Pharma Stocks Valuation: Why Multiples Run High

Sun Pharma trades at the lowest price to earnings ratio in this group at 38.61. Laurus Labs reports the highest return on equity at 22.11%. Cipla has the lowest price to book value at 3.15. These pharma stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this pharma stocks compared table: price to earnings and operating margin sit side by side so a high or low reading stands out at once.

Stock	Price to earnings	Price to book	ROE (%)	Dividend yield (%)	Debt to equity
Sun Pharma	38.61	4.75	13.79	0.90	0.04
Cipla	39.12	3.15	8.18	0.94	0.02
Mankind Pharma	45.15	5.81	12.76	0.04	0.31
Torrent Pharma	83.09	9.49	11.42	0.74	0.77
Laurus Labs	95.17	20.92	22.11	0.09	0.43

Pharma stocks trade at higher price to earnings multiples than the broader market because investors pay for steady demand and long product pipelines. That makes growth the main yardstick: a high multiple is easier to understand when revenue and profit are rising. Operating margin and return on equity add the quality check, and research spending tells you how much the company is investing for the future. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple pharma stock comparison like this one is only as useful as the context behind it, which is why revenue growth is worth checking as well.

In this group, price to earnings runs from 38.61 for Sun Pharma to 95.17 for Laurus Labs. Cipla offers the highest dividend yield at 0.94%. For reference, the industry price to earnings sits at 38.09, so you can see at a glance which stocks are rated above or below the group. A stock above that figure is being priced for a stronger pipeline or faster growth, while one below it is priced closer to the sector norm. A fair pharma stock comparison reads valuation next to growth, because pharma multiples are built on expectations. Run the same pharma stock comparison on your own watchlist and the pattern in these numbers will be easier to spot. Whenever you compare pharma stocks, note whether a premium is backed by returns or only by size.

Pharma Stocks Q2 FY27 Results: Revenue Growth Across the Group

All of the five pharma stocks compared have filed Q2 FY27 numbers. Torrent Pharma posted the fastest revenue growth at 51.7% year on year. Laurus Labs showed the sharpest rise in net profit at 125.4%. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. Treat the Q2 FY27 numbers in this pharma stocks compared review as a snapshot of one quarter, not a verdict on any drug maker.

Stock	Q2 FY27 revenue (Rs crore)	Q2 FY26 revenue (Rs crore)	Q2 FY27 net profit (Rs crore)	Q2 FY26 net profit (Rs crore)
Sun Pharma	16,716	14,948
Cipla	7,555	7,858
Mankind Pharma	4,433	3,789	716.1	520.2
Torrent Pharma	4,969	3,275
Laurus Labs	2,219	1,680	436.7	193.8

Sun Pharma Results Snapshot

Sun Pharma reported Q2 FY27 revenue of Rs 16,716 crore, compared with Rs 14,948 crore a year earlier, a rise of 11.8%. Net profit for the quarter was Rs 2,002 crore.

Cipla Results Snapshot

For the September 2026 quarter, Cipla booked revenue of Rs 7,555 crore. Net profit for the quarter was Rs 856.5 crore.

Mankind Pharma Results Snapshot

Mankind Pharma's Q2 FY27 top line stood at Rs 4,433 crore, versus Rs 3,789 crore in Q2 FY26, a rise of 17.0%. Net profit rose 37.7% to Rs 716.1 crore from Rs 520.2 crore. Operating margin expanded to 29.3% from 27.5% a year ago. Earnings per share for the quarter rose to Rs 17.20 from Rs 12.38.

Torrent Pharma Results Snapshot

Torrent Pharma reported Q2 FY27 revenue of Rs 4,969 crore, compared with Rs 3,275 crore a year earlier, a rise of 51.7%. Net profit for the quarter was Rs 534.0 crore.

Laurus Labs Results Snapshot

In the September 2026 quarter, Laurus Labs booked revenue of Rs 2,219 crore against Rs 1,680 crore in the same quarter last year, a rise of 32.1%. Net profit rose 125.4% to Rs 436.7 crore from Rs 193.8 crore. Operating margin expanded to 34.6% from 26.0% a year ago. Earnings per share for the quarter rose to Rs 8.16 from Rs 3.61.

Revenue grew at most of the five companies in the September quarter, though profit trends vary because launch timing, product mix and research costs differ. That variety is exactly why a pharma stock comparison should read both lines instead of relying on one. That is why a pharma stocks compared review works best with growth and margin shown beside every multiple. When you compare pharma stocks after each result season, track how revenue growth changes from one quarter to the next. A pharma stock comparison built on one quarter of data is a starting point, and the next set of results will update it.

Pharma Stocks Compared Two at a Time: Three Pairings

Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare pharma stocks two at a time.

Sun Pharma vs Cipla

Sun Pharma and Cipla are two of the best-known large pharma names and are often placed side by side. Sun Pharma is about 3.8 times the size of Cipla by market capitalisation, at Rs 4,24,202 crore against Rs 1,11,648 crore. On price to earnings, Sun Pharma carries the lower multiple at 38.61 against 39.12 for Cipla. Sun Pharma reports the higher return on equity, at 13.79% against 8.18% for Cipla. Both have broad portfolios, so read the revenue trend and operating margin to see how each is positioned for the next few quarters.

Mankind Pharma vs Torrent Pharma

Mankind Pharma and Torrent Pharma are both strong in domestic branded medicines and are often compared for their chronic therapy mix. On price to earnings, Mankind Pharma carries the lower multiple at 45.15 against 83.09 for Torrent Pharma. Mankind Pharma reports the higher return on equity, at 12.76% against 11.42% for Torrent Pharma. For dividend income, Torrent Pharma offers 0.74% against 0.04% at Mankind Pharma. With similar business models, differences in valuation and growth are what help you choose between them.

Laurus Labs vs Sun Pharma

Laurus Labs and Sun Pharma sit at different ends of the model range, one an ingredient and contract manufacturing player and the other a diversified medicine maker. Laurus Labs reports the higher return on equity, at 22.11% against 13.79% for Sun Pharma. For dividend income, Sun Pharma offers 0.90% against 0.09% at Laurus Labs. In Q2 FY27, Laurus Labs grew revenue faster, at 32.1% year on year against 11.8% for Sun Pharma. Laurus has shown fast profit growth from a smaller base, while Sun offers scale and breadth, so each suits a different reader.

Best Pharma Stocks by Investor Goal

Which of the best pharma stocks is right for you depends on your priorities, so the table below lists the leader on each measure instead of crowning one name. Any pharma stocks compared table can mislead if you stop at one row, because each drug maker leads on a different measure.

If you care most about	Start your research with	The number
Lowest price to earnings	Sun Pharma	38.61
Highest return on equity	Laurus Labs	22.11%
Highest dividend yield	Cipla	0.94%
Lowest price to book value	Cipla	3.15
Largest by market capitalisation	Sun Pharma	Rs 4,24,202 crore
Fastest Q2 FY27 revenue growth	Torrent Pharma	51.7%
Sharpest Q2 FY27 net profit rise	Laurus Labs	125.4%

Pharma valuations are rich, so growth and quality matter more than a low multiple. The investor-goal table gives you starting points, not a ranking.

What Is Driving Pharma Growth Right Now?

Pharma companies earn from the domestic branded market, regulated exports and contract manufacturing, and each model carries a different growth path. Chronic therapies, specialty launches and new product approvals have been important drivers. Knowing what moves launches and regulatory outcomes helps you compare pharma stocks with the right questions in mind.

Operating margin, research spending, product launches and regulatory inspection outcomes shape how the market rates each name. Domestic formulations players are tracked for field force productivity, while export-heavy names are tracked for approvals and pricing. A good pharma stocks compared routine therefore tracks operating margin, new launches, regulatory inspections and research spending.

Risks to Weigh When You Compare Pharma Stocks

Pharma stocks can move on regulatory observations, price controls, currency swings and the timing of product launches. Valuations in the sector are often higher than the broader market, which leaves less room for slips. Read each company's commentary on pipeline and compliance before you compare them. Every pharma stock comparison has blind spots, and for this group the biggest is launches and regulatory outcomes.

Because operating margin, new launches, regulatory inspections and research spending drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this pharma stocks compared guide a balanced starting point.

How to Compare Pharma Stocks and Build a Shortlist

Begin with scale and revenue growth to see which companies are expanding fastest, then use return on equity and price to earnings to judge quality against price. A premium multiple needs growth to support it. Done step by step, this pharma stocks compared routine becomes repeatable rather than a one-off exercise.

After that, read each company's commentary on launches, regulatory inspections and research spending. Holding two or three pharma names with different models, such as a diversified major and a domestic branded player, can reduce reliance on a single product cycle. Keep the shortlist of best pharma stocks short enough that you can actually follow each company's quarterly results. When you compare pharma stocks again after new results, update only the rows that changed instead of starting over.

The Univest stock screener lets you filter pharma stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this pharma stocks compared page after the next set of results to see which numbers have moved.

Check the Univest Screener for live pharma stock data

Download the Univest iOS App or Univest Android App to track these pharma stocks live.

Conclusion: Pharma Stocks Compared at a Glance

This pharma stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Sun Pharma leads on size and Laurus Labs leads on return on equity, while the others bring their own strengths. Treat the pharma stocks Q2 FY27 results and pharma stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare pharma stocks again next quarter, the same checklist of price to earnings, operating margin and revenue growth will work.

Frequently Asked Questions on Pharma Stocks Compared

Which are the top pharma stocks compared in this article?

Ans. The pharma stocks compared in this article are Sun Pharma, Cipla, Mankind Pharma, Torrent Pharma and Laurus Labs. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, so the group can be read in one sitting before you go deeper into any single company.

Which pharma stock has the highest market capitalisation?

Ans. Among the five names, Sun Pharma has the highest market capitalisation at Rs 4,24,202 crore. Torrent Pharma follows at Rs 1,74,402 crore. Market value changes with every price move, which means the ranking can shuffle, so look at the latest figure on the exchange.

Which of these pharma stocks has the lowest price to earnings ratio?

Ans. On pharma stocks valuation, Sun Pharma has the lowest price to earnings ratio among these pharma stocks at 38.61, based on the latest reported earnings. Laurus Labs sits at the other end at 95.17. Treat the lowest multiple as a place to start asking questions, because growth and business quality explain why investors pay more or less.

Which pharma stock has the highest return on equity?

Ans. Laurus Labs reports the highest return on equity in this group at 22.11%. In plain terms, return on equity tells you how hard shareholder funds are working. Read it across a few years and alongside debt, since a high ratio built on borrowing carries more risk.

How did pharma stocks perform in Q2 FY27 results?

Ans. All of the five names have filed Q2 FY27 numbers in our data. Torrent Pharma recorded the fastest revenue growth at 51.7% year on year. Laurus Labs showed the sharpest net profit rise at 125.4%. For pharma stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.

What are the main risks when you compare pharma stocks?

Ans. Pharma stocks can move on regulatory observations, price controls, currency swings and the timing of product launches. Valuations in the sector are often higher than the broader market, which leaves less room for slips. Read each company's commentary on pipeline and compliance before you compare them. Keep an eye on operating margin, new launches, regulatory inspections and research spending.

Which metrics matter most when you compare pharma stocks?

Ans. Revenue growth, operating margin, return on equity, price to earnings and research spending are the most useful numbers. Pharma multiples are high, so growth and margin trends help you judge whether the premium is justified. Product launches, regulatory inspection outcomes and the split between domestic and export sales explain much of the quarterly variation.

Which is the best pharma stock to buy among these five?

Ans. The best pharma stock depends on whether you value scale, domestic branded strength or fast growth from a smaller base. On the numbers in this article, Sun Pharma has the largest market capitalisation as well as the lowest price to earnings; Laurus Labs has the highest return on equity; Cipla has the highest dividend yield. There is no clear winner across every measure, and nothing here is a recommendation. Let the tables narrow your list, confirm the numbers in the filings, and take advice from a SEBI-registered advisor before acting.